Access THINK Advanced Therapeutics Pipeline Program
News Stories
Researchers and clinician researchers are invited to submit Expressions of Interest to access the resources of the THerapeutic INnovations for Kids (THINK) program Advanced Therapeutics Pipeline Program and discover how to identify exciting novel biology that can be translated into new therapeutics for childhood illnesses.
Led by A/Prof Greg Arndt, Head of the Australian Cancer Research Foundation (ACRF) Drug Discovery Centre at Children’s Cancer Institute, THINK is part of the Enabling Platforms Program funded by Luminesce Alliance.
View the introductory webinar slide presentation about how to submit an EOI
About Luminesce Alliance Precision Therapy Platform and THINK
The Luminesce Alliance Paediatric Precision Medicine Enabling Platforms are functional specialisations that cross disease areas and Luminesce Alliance member organisations. The (5) platforms provide support for leading clinicians and researchers to better understand and apply precision medicine.
THINK is one of two projects , otherwise known as programs , within The Precision Therapy Enabling Platform. This platform is designed to provide a pipeline that bridges the gap between scientific discovery and the development of new drugs for patients.
THINK was formed within Children’s Cancer Institute to accelerate the development and delivery of new treatments for children with cancer. The THINK program is a disease-agnostic integrated pipeline of technologies, capabilities, and expertise that spans all stages of the drug discovery and development pathway.
The overarching aim of the THINK program within the Luminesce Alliance Advanced Therapeutics Pipeline is to extend the THINK project portfolio to include not only cancer, but also new projects in rare genetic diseases and neurodevelopmental disorders.